Jarvis S M, Martin B W, Ng A S
Biochem Pharmacol. 1985 Sep 15;34(18):3237-41. doi: 10.1016/0006-2952(85)90340-5.
Human erythrocytes were shown to possess a saturable uptake mechanism for 2-chloroadenosine (apparent Km 23 microM, 22 degrees). Uptake by this route was inhibited by nitrobenzylthioinosine, uridine and adenosine, but adenine had no effect. In addition, uridine caused the countertransport of 2-chloroadenosine and vice versa. 2-Chloroadenosine was also shown to be an apparent competitive inhibitor of uridine influx (apparent Ki value of 33 microM) and high-affinity nitrobenzylthioinosine binding (apparent Ki 0.18 mM). The apparent Ki value for inhibition of uridine influx was close to the apparent Km value for 2-chloroadenosine uptake. Previous studies [Jarvis et al., Biochem. J. 208, 83 (1982)] have demonstrated that dog erythrocytes do not possess a saturable transport system for uridine and adenosine. Similarly, in the present study, the entry of 2-chloroadenosine into dog erythrocytes was slow and linear with concentration. Nitrobenzylthioinosine (NBMPR) had no effect on the uptake of 2-chloroadenosine into dog erythrocytes. These results demonstrate that 2-chloroadenosine enters human erythrocytes by the same nucleoside carrier as other nucleosides. It is suggested from these data that the previous explanation that the inability of nucleoside transport inhibitors to potentiate the pharmacological effects of 2-chloroadenosine was due to the failure of the nucleoside carrier to accept 2-chloroadenosine as a permeant may have to be reassessed.
已证明人类红细胞对2-氯腺苷具有可饱和的摄取机制(在22摄氏度时,表观Km为23微摩尔)。通过该途径的摄取受到硝基苄硫肌苷、尿苷和腺苷的抑制,但腺嘌呤没有作用。此外,尿苷会导致2-氯腺苷的反向转运,反之亦然。2-氯腺苷还被证明是尿苷流入的一种表观竞争性抑制剂(表观Ki值为33微摩尔)和高亲和力硝基苄硫肌苷结合的抑制剂(表观Ki为0.18毫摩尔)。抑制尿苷流入的表观Ki值接近2-氯腺苷摄取的表观Km值。先前的研究[贾维斯等人,《生物化学杂志》208, 83 (1982)]表明,犬红细胞不具有尿苷和腺苷的可饱和转运系统。同样,在本研究中,2-氯腺苷进入犬红细胞的过程缓慢且与浓度呈线性关系。硝基苄硫肌苷(NBMPR)对2-氯腺苷进入犬红细胞的摄取没有影响。这些结果表明,2-氯腺苷通过与其他核苷相同的核苷载体进入人类红细胞。从这些数据推测,先前关于核苷转运抑制剂无法增强2-氯腺苷药理作用是由于核苷载体不能接受2-氯腺苷作为通透剂的解释可能需要重新评估。